Tested medicines for drug-resistant lung tuberculosis
Part of Infections clinical trials.
This trial studies a specific drug combination (BPaLM) for adults with drug-resistant pulmonary (lung) tuberculosis. If you qualify, the goal is to see whether this treatment is effective and safe for your type of infection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 19 years old
- You weigh more than 35 kg (about 77 lb)
- You have confirmed rifampicin-resistant lung TB from recent sputum or bronchoscopy tests within 3 months
- Chest imaging shows changes consistent with pulmonary tuberculosis
- You do not have certain health problems that can make treatment unsafe (heart rhythm issues, severe diabetes, or serious medication allergies)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new oral medication combination (quabodepistat with other drugs) for people with drug-resistant pulmonary TB. It aims to find a shorter, safer, and more effective treatment.
This trial tests a combination of TB medicines (B-PaLMZ) for people with HIV who have their first episode of TB meningitis. It aims to find a better treatment option.
This trial tests a three-drug combination (bedaquiline, delamanid, and linezolid) to see if it's safe and works well for people with multi-drug resistant or rifampicin-resistant tuberculosis. It may offer a new treatment option if standard drugs aren't working.
This trial tests a shorter treatment regimen for people who have both diabetes and a type of tuberculosis (TB) that is resistant to the usual medicines. The goal is to see if the new treatment works well and is safe for this group.
This study is testing new combinations of drugs to treat tuberculosis (TB) in the lungs. It aims to find a more effective and shorter treatment, and you may benefit from receiving these new drugs while helping advance TB research.
This study tests different ways to treat active lung TB that is not resistant to rifampicin. It aims to find the best treatment duration and combination to cure TB and prevent it from coming back.
Hear when a new Multidrug- and Rifampicin-resistant Tuberculosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.